Turning $10,000 into $50,000 would be a massive result for any investor.
And while returns of that magnitude are certainly possible, they are far from common.
However, I think there are a handful of ASX shares with the potential to deliver huge growth over the next decade.
Here are two speculative investments I'd consider for that opportunity.

Image source: Getty Images
DroneShield Ltd (ASX: DRO)
DroneShield is one company I think has the potential to become much larger by 2035.
The defence technology specialist develops systems that detect and counter drones, serving a market that is expanding rapidly as governments invest in protecting military personnel, infrastructure, and public spaces.
And its recent growth has been impressive. During the first half of 2026, DroneShield increased revenue by 74% to $125.8 million.
Encouragingly, recurring revenue jumped 229% to $11.5 million as its installed base of software-enabled devices continued expanding.
I think this recurring revenue opportunity could be especially important over the coming decade.
As more customers deploy DroneShield's systems, the company has opportunities to generate ongoing revenue through software subscriptions, updates, and support services.
This could eventually make its earnings more predictable, cover fixed costs, and ultimately improve profitability.
The opportunity is material, but DroneShield still needs to demonstrate that it can consistently turn growing sales into profits.
Its first-half statutory net loss was $32.2 million, and its future will depend heavily on securing contracts, managing costs, and maintaining its technological advantage.
Nevertheless, I think DroneShield has the potential to become a much larger defence technology company by 2035.
4DMedical Ltd (ASX: 4DX)
My second ASX share is 4DMedical, which is developing technology to improve the diagnosis and treatment of respiratory diseases.
There are some similarities between 4DMedical and Pro Medicus Ltd (ASX: PME).
Both operate in medical imaging, developing specialised software that could become an important part of how healthcare providers diagnose and manage patients.
They also have the potential to benefit from highly scalable software business models.
Interestingly, Pro Medicus provided $10 million in strategic funding to 4DMedical in 2025 through an arrangement with equity-linked features.
I think that relationship is a positive given Pro Medicus' impressive track record in medical imaging.
And there's growing evidence that 4DMedical's technology is gaining traction. During the September quarter, the company processed a record 119,672 scans, an increase of 61% compared with a year earlier. Its software was also being delivered across 724 sites globally.
With gross margins exceeding 90%, I think there's a lot of potential for profitability to improve as revenue scales.
However, 4DMedical is still at a much earlier stage than Pro Medicus. It generated just $7.1 million in operating revenue during FY26 and remains loss-making.
For the shares to deliver exceptional returns, the company will need to turn its growing adoption into meaningful commercial revenue and eventually sustainable profits.
Could $10,000 really become $50,000 with these ASX shares?
For a $10,000 investment to become $50,000 by the end of 2035, it would need to generate approximately 19.6% annual returns over nine years.
That's an ambitious target, and neither company is guaranteed to achieve it.
Both could experience significant volatility, and investors could lose a good portion of their investment if growth disappoints.
Foolish takeaway
I think DroneShield and 4DMedical are ASX shares with the potential to deliver very strong long-term returns, although I would treat both as speculative investments.
Their markets offer significant growth opportunities, but there's a considerable difference between having exciting technology and building a consistently profitable business.
I'd be comfortable considering them as smaller positions within a diversified portfolio, giving their businesses time to develop while recognising that a fivefold return is far from guaranteed.